Asset-centricity is an approach to investing in the life sciences field with a focus on key assets, such as a pharmaceutical molecule that could form the basis for a novel new drug which has already been identified, rather than on discovering such assets through basic research & development.
[1][2][3] The asset-centric investing model is an attempt to streamline the drug discovery process, based on the widely held belief that it has become too expensive.
[2][4] It de-couples life sciences assets from the infrastructure necessary to develop them, with the goal of improving returns on invested capital.
[7][8] Forms of the asset-centric model have subsequently been adopted by other life sciences investment firms such as Atlas Venture and Symphony Capital.
[2] Examples of life sciences companies built on the asset-centric investing model include: